Advertisement

Familial Cancer

, 8:347 | Cite as

PALB2 sequence variants in young South African breast cancer patients

  • Michelle SluiterEmail author
  • Samantha Mew
  • Elizabeth J. van Rensburg
Article

Abstract

PALB2 (partner and localizer of BRCA2) is a recently identified breast cancer susceptibility gene, in which mutations confer doubling of breast cancer risk with moderate to low penetrance. Recent studies in various populations report that deleterious mutations in this gene account for approximately 1% of familial or early-onset breast cancer cases. This study aimed to determine the involvement of PALB2 mutations in a cohort of 48 young (29–45 years) South African breast cancer patients unselected for family history of breast cancer. The complete coding region and intron-exon boundaries of PALB2 were analyzed. A novel truncating mutation, c.697delG (V233fs) was identified in one patient. A missense variant (E211G), identified in another patient, appears to be segregating with the disease, but in silico analysis using SIFT, PolyPhen and A-GVGD, indicates that this variant is nonpathogenic. In addition, four other missense, one synonymous and three intronic variants were detected, all of which appear polymorphic. This represents the second study to analyze the role of PALB2 in early-onset breast cancer patients unselected for family history. The first study, of a Chinese population, established that PALB2 was responsible for 1.3% of early-onset breast cancer cases. Our study reports that deleterious mutations in PALB2 account for approximately 2% (1/48) of South African early-onset breast cancer.

Keywords

Early-onset breast cancer FANCN/PALB2 Mutation Sequence variation South Africa 

Notes

Acknowledgments

We thank the patients for volunteering to participate in this study and Celmari Dorfling for technical assistance. This study was supported by a research grant from the Cancer Association of South Africa (CANSA) to E.J.vR.

References

  1. 1.
    Ferlay J, Bray F, Pisani P, Parkin DM (2004) Cancer incidence, mortality and prevalence worldwide. GLOBOCAN 2002, IARC cancerbase No. 5, version 2.0. IARCPress, LyonGoogle Scholar
  2. 2.
    Mqoqi N, Kellet P, Madhoo J, Sitas F (2004) Incidence of histologically diagnosed cancer in South Africa, 1998–1999. National Cancer Registry of South Africa, National Health Laboratory Service, JohannesburgGoogle Scholar
  3. 3.
    Miki Y, Swenson J, Shattuck-Eidens D et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66–71CrossRefPubMedGoogle Scholar
  4. 4.
    Wooster R, Bignell G, Lancaster J et al (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789–791CrossRefPubMedGoogle Scholar
  5. 5.
    Reeves MD, Yawitch TM, van der Merwe NC et al (2004) BRCA1 mutations in South African breast and/or ovarian cancer families: evidence of a novel founder mutation in Afrikaner families. Int J Cancer 110:667–682CrossRefGoogle Scholar
  6. 6.
    van Rensburg EJ, van der Merwe NC, Sluiter MD and Schlebusch CM (2007) Impact of the BRCA-genes on the burden of familial breast/ovarian cancer in South Africa [Abstract 382]. Presented at the annual meeting of the American Society of Human Genetics, October 2007, San Diego, California. Available from http://www.ashg.org/genetics/ashg07s/search_page-04.shtml
  7. 7.
    Venkitaraman AR (2004) Tracing the network connecting BRCA and Fanconi anaemia proteins. Nat Rev Cancer 4:266–276CrossRefPubMedGoogle Scholar
  8. 8.
    Wooster R, Weber BL (2003) Breast and ovarian cancer. N Engl J Med 348:2339–2347CrossRefPubMedGoogle Scholar
  9. 9.
    Xia B, Sheng Q, Nakanishi K et al (2006) Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 22:719–729CrossRefPubMedGoogle Scholar
  10. 10.
    Howlett NG, Taniguchi T, Olson S et al (2002) Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297:606–609CrossRefPubMedGoogle Scholar
  11. 11.
    Reid S, Schindler D, Hanenberg H et al (2007) Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet 39:162–164CrossRefPubMedGoogle Scholar
  12. 12.
    Xia B, Dorsman JC, Ameziane N et al (2007) Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet 39:159–161CrossRefPubMedGoogle Scholar
  13. 13.
    Kutler DI, Singh B, Satagopan J et al (2003) A 20-year perspective on the international Fanconi Anemia registry (IFAR). Blood 101:1249–1256CrossRefPubMedGoogle Scholar
  14. 14.
    Erkko H, Xia B, Nikkila J et al (2007) A recurrent mutation in PALB2 in Finnish cancer families. Nature 446:316–319CrossRefPubMedGoogle Scholar
  15. 15.
    Garcia MJ, Fernandez V, Osorio A et al (2009) Analysis of FANCB and FANCN/PALB2 Fanconi Anemia genes in BRCA1/2-negative Spanish breast cancer families. Breast Cancer Res Treat 113:545–551. doi:  10.1007/s10549-008-9945-0 CrossRefPubMedGoogle Scholar
  16. 16.
    Rahman N, Seal S, Thompson D et al (2007) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 39:165–167CrossRefPubMedGoogle Scholar
  17. 17.
    Tischkowitz M, Xia B, Sabbaghian N et al (2007) Analysis of PALB2/FANCN-associated breast cancer families. Proc Natl Acad Sci USA 104:6788–6793CrossRefPubMedGoogle Scholar
  18. 18.
    Foulkes WD, Ghadirian P, Akbari MR et al (2007) Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women. Breast Cancer Res 9:R83CrossRefPubMedGoogle Scholar
  19. 19.
    Walsh T, King MC (2007) Ten genes for inherited breast cancer. Cancer Cell 11:103–105CrossRefPubMedGoogle Scholar
  20. 20.
    Cao AY, Huang J, Hu Z et al (2009) The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives. Breast Cancer Res Treat 114:457–462. doi: 10.007/s10549-008-0036-z CrossRefPubMedGoogle Scholar
  21. 21.
    Johns MB Jr, Paulus-Thomas JE (1989) Purification of human genomic DNA from whole blood using sodium perchlorate in place of phenol. Anal Biochem 180:276–278CrossRefPubMedGoogle Scholar
  22. 22.
    Rozen S, Skaletsky H (2000) Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 132:365–386PubMedGoogle Scholar
  23. 23.
  24. 24.
    den Dunnen JT, Antonarakis SE (2000) Mutation nomenclature extensions and suggestions to describe complex mutations: A discussion. Hum Mutat 15:7–12CrossRefGoogle Scholar
  25. 25.
  26. 26.
    Ramensky V, Bork P, Sunyaev S (2002) Human non-synonymous SNPs: server and survey. Nucleic Acids Res 30:3894–3900CrossRefPubMedGoogle Scholar
  27. 27.
  28. 28.
    Ng PC, Henikoff S (2003) SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res 31:3812–3814CrossRefPubMedGoogle Scholar
  29. 29.
  30. 30.
    Tavtigian SV, Deffenbaugh AM, Yin L et al (2006) Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J Med Genet 43:295–305CrossRefPubMedGoogle Scholar
  31. 31.
    Tavtigan SV, Greenblatt MS, Lesueur F et al (2008) In silico analysis of missense substitutions using sequence-alignment based methods. Hum Mutat 29:1327–1336CrossRefGoogle Scholar
  32. 32.
    Armougom F, Moretti S, Poirot O et al (2006) Expresso: automatic incorporation of structural information in multiple sequence alignments using 3D-Coffee. Nucleic Acids Res 34:W604–W608CrossRefPubMedGoogle Scholar
  33. 33.
  34. 34.
  35. 35.
    Tischkowitz M, Easton DF, Ball J et al (2008) Cancer incidence in relatives of British Fanconi Anaemia patients. BMC Cancer 8:257–261CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  • Michelle Sluiter
    • 1
    Email author
  • Samantha Mew
    • 1
  • Elizabeth J. van Rensburg
    • 1
  1. 1.Department of GeneticsUniversity of PretoriaPretoriaSouth Africa

Personalised recommendations